QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,763 signal articles · 238 in last 24h · 109,262 total before filter · latest 1h ago
238last 24h
2522last 7d
474● bullish (7d)
240● bearish (7d)
202publishers
AllMacro231Earnings1565M&A105Regulatory18Product12Analyst24
Sentiment:bullishneutralbearishshow all (incl. clickbait)
Sirius XM (SIRI) Misses Q2 Earnings Estimates
Zacks11d agobearish
Sirius XM (SIRI) Misses Q2 Earnings Estimates

Sirius XM (SIRI) delivered earnings and revenue surprises of -10.26% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Stocks Bounce Back From Fed Day Turmoil
Barrons.com11d agoneutral
Stocks Bounce Back From Fed Day Turmoil

Stocks kicked off Thursday’s trading session higher, reemerging from the carnage of Wednesday’s selloff. The S&P 500 was up 0.9%, while the Nasdaq Composite rose 1.6%. Rosenberg Research’s Dave Rosenberg described the moves as “a weak stock-market bound on shaky ground,” nodding to the major averages’ “precarious technical positions,” yesterday’s rise in bond yields, and oil price spikes.

Microsoft Surges 9% as Azure Tops $100B and Q4 Beat Lifts Most Price Targets
24/7 Wall St.11d agobullish
Microsoft Surges 9% as Azure Tops $100B and Q4 Beat Lifts Most Price Targets

Shares of Microsoft (NASDAQ:MSFT) are up 9% in early Thursday trading, changing hands at $427 after the software giant delivered a fiscal fourth-quarter blowout and crossed a symbolic Azure milestone. The pop lifts the stock off Wednesday’s $390.54 close and pushes it back toward levels last seen in the spring. As of yesterday’s close, Microsoft ... Microsoft Surges 9% as Azure Tops $100B and Q4 Beat Lifts Most Price Targets

Sanofi Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Sanofi Q2 Earnings Call Highlights

Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongo

Stock Futures Unfazed by Cooler Inflation and Slow Economic Growth
Barrons.com11d agoneutral
Stock Futures Unfazed by Cooler Inflation and Slow Economic Growth

The market got a fresh batch of economic data, with new personal consumption expenditures and gross domestic product data released ahead of the opening bell. Inflation data came in cooler than expected. Core PCE, which excludes food and energy costs and is closely watched by the Federal Reserve, rose 0.1% from the month prior, below consensus estimates of 0.2% and the 0.3% increase seen in May. Headline PCE was roughly in line with expectations.